Preventing Group B Streptococcal Infections: New Recommendations

Davies, H. Dele

doi:10.1155/2002/352613

Cited by 3 publications

(2 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Globally, GBS is a leading cause of neonatal morbidity and mortality ( 8 , 26 , 29 – 31 ). Approximately 30% of women are naturally colonized with GBS, including those that are pregnant ( 32 ).…”

Section: Discussionmentioning

confidence: 99%

Epidemiological Characterization of Group B Streptococcus Infections in Alberta, Canada: An Update from 2014 to 2020

Thompson

Corsiatto

et al. 2021

Microbiol Spectr

View full text Add to dashboard Cite

This work describes the epidemiology of invasive infections caused by the bacterium group B Streptococcus (GBS) in Alberta, Canada. We show that rates of invasive GBS disease have increased from 2014 to 2020 for both adult disease and late-onset disease in neonates, whereas the rate of early onset disease in neonates has decreased. We also show that the rate of resistance to erythromycin (an antibiotic used to treat GBS) has also increased in this time.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiological Characterization of Group B Streptococcus Infections in Alberta, Canada: An Update from 2014 to 2020

Thompson

Corsiatto

et al. 2021

Microbiol Spectr

View full text Add to dashboard Cite

show abstract

“…We developed and demonstrated a CRISPR-based assay that offered short turn-around time and great sensitivity, which makes it a potential rapid, pointof-care assay for intrapartum GBS diagnosis, even in low-resource settings. Debates have occurred over approaches of preventing neonatal diseases caused by GBS infection (25). However, both of the 2 commonly used conventional strategies (i.e., risk-based screening or late antenatal microbiologic testing) have their own limitations (3,26).…”

Section: Discussionmentioning

confidence: 99%

Development and Clinical Evaluation of a CRISPR-Based Diagnostic for Rapid Group BStreptococcusScreening

Jiang¹,

Zeng²,

Wu³

et al. 2021

Emerg. Infect. Dis.

View full text Add to dashboard Cite

G roup B Streptococcus (GBS) is a common commensal bacteria of vaginal fl ora with reported carriage rates of 4%-40% (1-3). Vertical transmission of (GBS) through fetal aspiration of infected amniotic fl uid or during birth canal passage has been considered one of the most important causes of neonatal illness and death (3,4). GBS colonization during pregnancy has been a leading cause of severe neonatal infectious diseases, including sepsis, pneumonia, and meningitis (5,6). Early onset neonatal infections can be prevented in most cases by providing intrapartum antibiotic prophylaxis to the colonized mother (7). However, GBS carriages are often intermittent, and the rate of GBS colonization varies during pregnancy (1,8). On the other hand, use of antibiotic prophylaxis solely relying on risk assessment leads to unnecessary treatment in many women. Therefore, determination of colonization at the time of delivery is crucial for the prevention of neonatal infection (9).Culture-based methods remain the most commonly used screening practice and the standard for GBS detection; however, because of technical limitations, including turnaround time, pregnant women are usually screened for GBS at 35-37 weeks of gestation (6). As many studies have pointed out, the predictive value of GBS decreases as the interval time increases between screening and delivery (10,11). These studies underlie the needs for a more rapid and sensitive diagnostic for intrapartum GBS screening.CRISPR/Cas has been widely used as a programmable tool for gene editing and other in vivo applications since 2013 (12-14). However, recently, the collateral, promiscuous cleavage activities of a unique group of Cas enzymes were discovered and harnessed for in vitro nucleic acid detection (15)(16)(17).To address the unmet clinical needs for GBS screening, we developed CRISPR-GBS, a novel CRIS-PR/Cas13-based in vitro diagnostic assay, and conducted a prospective cohort study and a validation study in >400 clinical cases to evaluate its diagnostic performance among different technology platforms, including culture and PCR-based methods. Our fi ndings demonstrate that CRISPR-GBS is rapid and easy-

show abstract

Détection de la colonisation par Streptococcus agalactiae: étude prospective comparant l'amplification génique en temps réel à un nouveau milieu chromogène Strepto B ID

Grandjean¹,

Goffinet²,

Hougardy³

2007

Pathologie Biologie

View full text Add to dashboard Cite

Preventing Group B Streptococcal Infections: New Recommendations

Cited by 3 publications

References 46 publications

Epidemiological Characterization of Group B Streptococcus Infections in Alberta, Canada: An Update from 2014 to 2020

Epidemiological Characterization of Group B Streptococcus Infections in Alberta, Canada: An Update from 2014 to 2020

Development and Clinical Evaluation of a CRISPR-Based Diagnostic for Rapid Group BStreptococcusScreening

Détection de la colonisation par Streptococcus agalactiae: étude prospective comparant l'amplification génique en temps réel à un nouveau milieu chromogène Strepto B ID

Contact Info

Product

Resources

About